Quantcast

Latest Anaplastic lymphoma kinase Stories

2015-06-01 08:34:12

- In Phase II studies, Zykadia (ceritinib) shrank tumors in patients with ALK+ NSCLC; comparable overall response in those with or without brain metastases1,2 EAST HANOVER, N.J., June 1, 2015

2015-05-06 08:32:07

- Marks first commercial oncology milestone for EMD Serono through the global strategic alliance between Merck KGaA, Darmstadt, Germany and Pfizer ROCKLAND, Mass., May 6, 2015 /PRNewswire/

2015-04-14 08:21:13

PORTLAND, Ore.

2015-02-27 23:18:08

A study published in The Oncologist on February 26, 2015, challenges the role of fluorescence in situ hybridization (FISH) testing as the current gold standard for detecting EML4-ALK rearrangements

2015-01-21 08:29:23

TUCSON, Ariz., Jan. 21, 2015 /PRNewswire/ -- Ventana Medical Systems, Inc.

2015-01-10 23:01:55

The Oncology Institute of Hope and Innovation announces first clinical trial of the year. Downey, CA (PRWEB) January 10, 2015 The Oncology Institute

2014-11-10 12:28:58

-- CHOP and Penn Medicine Experts Define Riskier Mutations in Neuroblastoma, Setting Stage for Clinical Trial-- PHILADELPHIA, Nov.

2014-08-18 23:02:59

The anti-cancer drug Xalkori® is being investigated by the ECOG-ACRIN Cancer Research Group in E4512, a phase III trial. Philadelphia, PA (PRWEB) August

2014-06-03 11:22:42

A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).


Word of the Day
typomania
  • A mania for the use of printing-types; a strong propensity to write for publication.
The word 'typomania' comes from Greek roots meaning 'type' and 'madness'.